

The regulatory storm is approaching the MedTech industry




---

---

---

---

---

---

---

---

QAdvis key competence areas

QMS in-the cloud

Turn key QMS  
Digital signatures  
Efficient and lean  
Validated and compliant

System development

Project management  
Product software validation  
Regulated software validation  
Requirement management  
Risk management  
Verification and validation  
Process validation

QA&RA/Clinical Consulting

Interim management  
Expert advice  
Audits/Block audits/Due diligence  
Warning letters, compliance projects  
PMA, 510k, CE-mark  
Global regulatory support  
Vigilance, recall, post market surveillance  
Clinical evaluation and clinical studies

Training/courses

CE-marking  
ISO 13485 & 21CFR820  
IEC 62304 & IEC 82304-1  
IEC 60601-1  
IEC 62366-1  
SW life cycle  
SW risk management  
Risk management  
And more....

Lean and Six Sigma

Training and Consulting  
In cooperation with USA based partner.

European Authorized Representation

Providing European representation for non-EU MedTech companies  
Active board member of EAAR: European Association of Authorized Representatives




---

---

---

---

---

---

---

---

Presentation of the speaker Robert Ginsberg



30+ years in SW Development  
25+ years in Medical Device SW  
Participated in > 20 audits, FDA, MDD, etc.  
Certified Lead auditor (ISO 13485 & QSR)  
Co-author to IEC 62304 and IEC, 82304-1  
SW Expert EU SW Workgroup  
Chairman of board of QAdvis




---

---

---

---

---

---

---

---

**Agenda**



- Introduction and background
- Medical Device Regulation (MDR) highlights
- Conformity routes and classification
- Technical Documentation
- General Safety and Performance Requirements (GSPR)
- Quality Management System (QMS)
- Timelines and implementation
- Additional information
- Questions and answers
- QAdvis services




---

---

---

---

---

---

---

---



**Background**




---

---

---

---

---

---

---

---

**Major changes for medical device and IVD device industry are ahead of us**

- EU regulations
- Non-EU regulations
- Standards
- Brexit

Affecting all stakeholders: manufacturers, distributors, competent authorities, notified bodies, and many more

**At the same time!**




---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### EU Regulations for medical devices are not far away, two years

Medical Device Directive 93/42/EEC and Active Implantable Medical Device Directive 90/385/EEC are replaced by **Medical Device Regulation 2017/745**

End date May 2020  
Lasted 24 and 27 years -> RIP

QAAdvis

---

---

---

---

---

---

---

---

**EU Regulations for IVDs have five years transition time**

In-vitro Diagnostic Medical Device Directive 98/79/EC is replaced by

**In-vitro Medical Device Regulation 2017/746**

End date May 2022



---

---

---

---

---

---

---

---

**EU - Medical Device Regulation 2017/745 (MDR)**

All current CE-marked devices need to be re-CE marked to survive 2020 + (4 years for class Im, Is or higher if "unchanged")

All new devices must meet MDR after May 2020 to be CE marked

**There is no "grandfathering" - at all!**



---

---

---

---

---

---

---

---

**Notified Bodies need to reapply for MDR**

All Notified Bodies lose accreditation for MDD, in May 2020  
Need decide and apply for designation for MDR, in Nov 2017



---

---

---

---

---

---

---

---

**You need to be aware – and act**

Strategy for current product portfolio - regulatory aspects  
Strategy for future product portfolio – regulatory aspects



**Time is limited!**



---

---

---

---

---

---

---

---

**MDR is very dense with information**

It takes time to read it, digest and understand



---

---

---

---

---

---

---

---

**EU - Medical Device Regulation 2017/745 (MDR)**

- Some important aspects
- ⇒ New classification assessment
- ⇒ New conformity routes to meet
- ⇒ New Essential Requirements (General Safety Performance Requirements)
- ⇒ Much stricter requirements for Clinical data
- ⇒ New labelling requirements, Unique Device Identification (UDI)
- ⇒ Much stricter classification for Software as Medical Device (SaMD)



---

---

---

---

---

---

---

---

**MDR classification, several changes**

**Examples**

**Rule 20 – new rule**  
Inhalation of medicinal products  
- Class IIa or IIb

**Rule 21 – new rule**  
Substances intended to be introduced into the human body  
via a body orifice or applied to the skin – Class IIa, IIb or III

**Conclusion:** Change of class? Need for NB? (Portfolio strategy)

NB = Notified Body



---

---

---

---

---

---

---

---

**The expectations on Clinical Evaluations will be challenging to fulfil**

- Update Clinical Evaluation reports
- Need sufficient clinical data
- Claim equivalence with other products much more difficult
  - require continuous access to technical documentation and a contract with the (competitor) manufacturers
  - technical documentation referenced shall be based on MDR

**Conclusion:** More clinical data may be needed. PMCF may be initiated (**now!**) for “re-CE marking”. (Portfolio strategy)

PMCF = Post Market Clinical Follow-up



---

---

---

---

---

---

---

---

**Prepare your company for the MDD to MDR transition**

Analyze and form your MDR (and IVDR) strategy for your products



---

---

---

---

---

---

---

---

**Medical Device Regulation affect many roles**

- Some important distribution/import aspects
- ⇒ New requirements for distributors to verify compliance of products, report
- ⇒ New requirements for importers to verify compliance of products
- ⇒ New requirements for authorized representatives to verify compliance of products




---

---

---

---


---

---

---

---

**A distribution chain can be complex**



EAR = European Authorized Representative




---

---

---

---

---

---


---

---

**Who is responsible for what?**

Your QMS must handle it all

Quality contracts with distributors, suppliers, authorized representatives, importers, etc.



Eudamed!




---

---

---

---

---

---

---

---

**Your Quality Management System (QMS) needs to be updated**

QMS compliance and integrity shall be maintained during changes  
MDR, IVDR transition plan needed  
QMS must handle both MDD and MDR requirements during next 3-5 years.

ISO 13485:2016 entering its last transition year. March 2019  
ISO 9001:2015 end of transition period in Sept 2018



---

---

---

---

---

---

---

---

**CE-mark is used also outside EU**



CE-mark used in several other jurisdictions as means for regulatory approval  
Declaration of Conformity (DoC)  
EC certificate

**Need to confirm with each country**



---

---

---

---

---

---

---

---

**Medical Device Single Audit Program (MDSAP)**

Quality system audit harmonization initiative to satisfy the requirements of multiple regulatory jurisdictions.

Current participants: USA, Brazil, Canada, Japan, Australia

Canada requires MDSAP from 1<sup>st</sup> Jan 2019 (CMD CAS removed)



---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

### Prepare your company for the MDD to MDR transition

Analyze and form your MDR strategy to meet the timelines

The cartoon shows a person in a brown suit and hat riding a red rocket labeled 'HELP!' off the edge of a cliff. The person is holding a sign that says 'HELP!'. The background is a blue sky with clouds.

---

---

---

---

---

---

---

---

---

---

**Brexit add more uncertainty and additional work**



UK based Notified Bodies  
(move before MDR=> new number)

UK based Authorized Representatives  
(massive drop out or move to EU)

Will UK adopt a UK-version of MDR and IVDR or something else?

Will UK be part of Eudamed database?

Specific vigilance reporting to UK?




---

---

---

---


---

---

---

---

**Notified Bodies will drop out or limit their scope**




---

---

---

---

---

---

---

---

**Notified Bodies – Drop of number and scope**

**Uncertainty**

- Which NB:s will apply for designation for MDR & IVDR?
- What scope will they apply for?
- Company product range may need 2 or more NB:s
- Shortage of trained qualified personnel
- Race for NB:s
- No NB certification in time = no CE mark




---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---

Delegated acts - Implementing acts



- **Delegated acts**  
Acts used to modify or amend the regulation.
- **Implementing acts**  
Acts used to clarify and explain how the regulations should be interpreted and used.

QAdvis

---

---

---

---

---

---

---

---

Common specifications (CS)



- When there are no harmonized standards or the harmonized standards are not sufficient, the Commission can adopt a common specification
- For example for devices with non-medical purpose and single use devices to be re-processed

(Article 2 (71))

QAdvis

---

---

---

---

---

---

---

---

A person responsible for regulatory compliance is needed



- Manufacturer shall have available within their organization at least one person responsible for regulatory compliance.

(Article 15)




---

---

---

---

---

---

---

---

Additional products covered by MDR



- Annex XVI defines products without an intended medical purpose.
- Common specifications is to be developed for these product groups.

(Article 1 (2) / Annex XVI)




---

---

---

---

---

---

---

---



Eudamed




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

Unique Device Identification (UDI) system

"Unique Device Identifier (UDI) means a series of numeric or alphanumeric characters that is created through internationally accepted device identification and coding standards and that allows unambiguous identification of specific devices on the market."

(Article 27)

---

---

---

---

---

---

---

---

---

---

UDI consists of two parts DI and PI

UDI = DI+PI

Machine readable format

Human readable format

Device Identifier (DI)

Production Identifier (PI)

---

---

---

---

---

---

---

---

---

---

Implant card is needed for more devices



Information allowing the identification of the device implanted

- Device name, serial number, lot number, UDI, device model, manufacturer and contact details to manufacturer, webpage
- Warnings and precautions to take
- Life time of device and necessary follow up

(Article 18)




---

---

---

---

---

---


---

---

---

---

UDI is a multidisciplinary task




---

---

---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

Conformity routes – product classes are unchanged under MDR

- Conformity route to be selected for each device category – different routes to chose between depending on classification of device
- Involvement of Notified Body differs depending on assessment route and device classification

(Article 52)

---

---

---

---

---

---

---

---

Conformity routes are “renumbered” under MDR

- **Annex IX** – Conformity assessment based on a quality management system and on assessment of technical documentation
- **Annex X** – Conformity assessment based on type-examination
- **Annex XI** – Conformity based on product conformity verification
  - Part A – Production quality assurance
  - Part B – Product verification
- **Annex XIII** – Procedures for custom-made devices

(Article 52)

---

---

---

---

---

---

---

---

Classification

---

---

---

---

---

---

---

---

**Classification rules overview**



- Non-invasive devices: Rule 1-4
- Invasive devices: Rule 5-8
- Active devices: Rule 9-13
- Special rules: Rule 14-22

(Annex VIII)




---

---

---

---

---

---

---

---

**Classification rules news and updates**



- Rule 8 – addition  
Active implantable devices, breast implants or surgical meshes, joint replacement, spinal disc replacement implants – class III
- Rule 19 – new rule  
Incorporating nanomaterial – Class IIa, IIb or III
- Rule 20 – new rule  
Inhalation of medicinal products – Class IIa or IIb
- Rule 21 – new rule  
Substances intended to be introduced into the human body via a body orifice or applied to the skin – Class IIa, IIb or III

(For complete wording, see Annex VIII)




---

---

---

---

---

---

---

---

**There is a new classification rule in MDR for SaMD – rule 11**



Software intended to provide information which is used to take decisions with diagnosis or therapeutic purposes – **Class IIa**

- May cause death – **Class III**
- May cause serious deterioration of state of health or surgical intervention – **Class IIb**
- Monitoring of physiological processes – **Class IIa**
- Monitoring of vital physiological parameters, variations of those parameters could result in immediate danger – **Class IIb**
- All other software – **Class I**

(For complete wording, see Annex VIII of MDR)




---

---

---

---

---

---

---

---

Rule 11 will change classification for many SaMD



- Many SaMD will get a classification of Class IIa or higher based on this rule
- Need of a Notified Body for class IIa or higher
  - Certified Quality Management System
  - External review of technical documentation
- Interpretation issues not resolved so far
- Potential implications are not fully explored
- In opposite direction to USA and 21st Century Cures Act for mobile devices

SaMD = Software as Medical Device




---

---

---

---

---

---

---

---



Technical Documentation




---

---

---

---

---

---

---

---

Technical Documentation - Overview



- Technical Documentation (Annex II)
- Technical Documentation on PMS (Annex III)
- DoC (Annex IV)
- GSPR (Annex I)
- Clinical Evaluation (Annex XIV)

(Annex I, II, III, IV, XIV)

PMS = Post Market Surveillance




---

---

---

---

---

---

---

---

**Technical Documentation – Contents**

No.	Description
1	Device description and specification
2	Information to be supplied by the manufacturer
3	Design and manufacturing information
4	General safety and performance requirements
5	Benefit-risk analysis and risk management
6	Product verification and validation

UDI, rationale for MD, classification  
 UDI, indication for MD, substances? importer?  
 Identification of all sites, suppliers and subcontractors  
 More: Update structure, DoC  
 Clinical evaluation, additional requirements on substances  
 Make sure Annex I (1, 3, 8) is fulfilled  
 Update entire checklist!

(Annex II) 

---

---

---

---

---

---

---

---

---

---



**General Safety and Performance Requirements (GSPR) and more**



---

---

---

---

---

---

---

---

---

---

**General Safety and Performance Requirements (GSPR)- Overview**



- Change from MDD Essential Requirements (ER) to General Safety and Performance Requirements (GSPR)
- Checklist recommended
- Method of compliance
- Reference to evidence of compliance

(Annex I) 

---

---

---

---

---

---

---

---

---

---

**GSPR are more detailed and demanding than Essential Requirements**



- Risk based approach – Stronger connection to Risk Management
- Annex XVI products included (no medical purpose)
- Clinical evaluation requirement deleted from Annex I (ER 6a). Included in Article 61, Annex XIV and Annex II.
- Requirements for active implantable devices added
- Substances specified with limitations
- Risk of particles released
- Risks with software and IT environment

(Annex I)




---

---

---

---

---

---

---

---



Clinical Evaluation




---

---

---

---

---

---

---

---

**Clinical Evaluation – Extent based on**



- Nature
- Classification
- Intended purpose
- Risks
- Manufacturer’s claims

(Annex XIV)




---

---

---

---

---

---

---

---

**Clinical Evaluation – Equivalence**



May be based on equivalent devices

- Technical equivalence, and
- Biological equivalence, and
- Clinical equivalence

Sufficient levels of **access to the data** in order to justify their claims of equivalence

(Annex XIV, Article 61)




---

---

---

---

---

---

---

---

**Clinical Evaluation – Product Assessment**



- Based on equivalence?
- Clinical evidence sufficient?
- Need of new clinical trials?
- Need of PMCF?
- MEDDEV 2.7/1 Rev 4?
  - Guidance, not legally binding
  - State of the art?
  - Inspiration
  - Recommendation; Follow MEDDEV 2.7/1 Rev 4 and make sure that Clinical Evaluation according to MDR is fulfilled.

(Annex XIV, Article 61)

PMCF = Post Market Clinical Follow-up




---

---

---

---

---

---

---

---



Quality Management System




---

---

---

---

---

---

---

---

General obligations of manufacturers



- Requirements on
  - Quality Management System
  - Manufacturing and design
  - Clinical evaluations
  - UDI system
  - Risk management
  - Technical documentation and DoC
  - Vigilance
  - Post market surveillance system

(Article 10) DoC = Declaration of Conformity




---

---

---

---

---

---

---

---



Implementation




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---

**MDR Conclusions**



- MDR is published
- A lot of work – start now!
- No grandfathering:  
Not ready in time = products can not be placed on the market
- Stricter requirements on all players (Authorities, Notified Bodies and Manufacturers)
- Sufficient clinical evidence necessary
- Many products will be up-classified

(Annex VIII)




---

---

---

---

---

---

---

---

**Make the plan, now!**






---

---

---

---

---

---

---

---

**Thank you for your attention**  
**Questions & Answers**





---

---

---

---

---

---

---

---

**QAdvis services**



- GAP analysis and implementation plan
- Quality Management System
- Auditing
- Technical Documentation
- Clinical Evaluation
- Risk management
- Courses
  - MDR
  - CE marking
  - ISO 13485:2016
  - Software validation
  - Risk management & SW risk management
- Internal trainings
- Product specific workshop

Contact  
[robert.ginsberg@qadvis.com](mailto:robert.ginsberg@qadvis.com)



---

---

---

---

---

---

---

---

**Training course, examples**



**EU Medical Device Regulation Course**  
MDD to MDR - Key changes and implementation  
Prepare your organization for the transition

**Our services include:**

- Quality management support
- System development
- Clinical evaluation
- Medical device software specialist services
- Regulated software validation
- Quality and regulatory consulting
- Training
- European Authorized Representation

**Introduction and aim**  
Your organization has an upcoming challenge in implementing the Medical Device Regulation (MDR). This will probably lead to many questions and concerns about how to make this work efficiently and value adding. Sign up for our interactive one-day course on the new Regulation, and learn about the changes and how to implement the requirements in your organization. Let QAdvis guide you in this world!



---

---

---

---

---

---

---

---